ImmunoGen Announces Agreements to Exchange $76.4 Million of Its 4.50% Convertible Senior Notes Due 2021 for Common Stock
The Company anticipates that the exchanges will be completed on or about
This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering would be unlawful. The exchanges are exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended.
About ImmunoGen
ImmunoGen is a clinical-stage biotechnology company that develops
targeted cancer therapeutics using its proprietary antibody-drug
conjugate (ADC) technology. ImmunoGen's lead product candidate,
mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive
platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in
combination regimens for earlier-stage disease. ImmunoGen's ADC
technology is used in Roche's marketed product, Kadcyla®, in other
clinical-stage ImmunoGen product candidates, and in programs in
development by Amgen, Bayer, Biotest, CytomX,
Kadcyla® is a registered trademark of
This press release includes forward-looking statements based on
management's current expectations. These statements include, but are not
limited to, ImmunoGen's expectations related to: the completion of the
exchanges on or about
View source version on businesswire.com: http://www.businesswire.com/news/home/20170901005176/en/
For Investors
sarah.kiely@immunogen.com
or
For
Media
Courtney O'Konek, 781-895-0158
courtney.okonek@immunogen.com
or
FTI
Consulting, Inc.
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com
Source:
News Provided by Acquire Media